Praxis Precision Medicines (PRAX) Fireside Chat summary

Introduction and agenda

• Special edition call convened to discuss recent developments and hot topics, including the re-rating that broadened investor interest.

• Focus on Relutrigine and Ulixacaltamide, with updates on clinical progress and regulatory strategy.

Current industry trends

• Accelerated regulatory pathways and Breakthrough Therapy Designation are shaping development timelines.

• Increased investor and patient interest in rare epilepsy and essential tremor treatments.

Challenges and overcoming obstacles

• Navigated regulatory uncertainty by maintaining close dialogue with the FDA and adapting study designs.

• Addressed the need for robust efficacy data while balancing safety database requirements.

• Overcame recruitment challenges by investing in data-driven site selection and patient identification.